ReutersSanofi wins EU approval for Praluent anti-cholesterol drugReutersPARIS French drugmaker Sanofi said the European Commission had cleared its key cholesterol drug Praluent for the treatment of so-called "bad cholesterol," or low-density lipoprotein (LDL) cholesterol, in certain adult patients with hypercholesterolemia.Regeneron and Sanofi Announce Approval of Praluent® (alirocumab) for the ...MarketWatchall 5 news articles »
Sanofi wins EU approval for Praluent anti
Rating: 4.5
Diposkan Oleh: Unknown
